SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, invented in the lab of Stanford scientist Dr. Jeffrey Glenn, targets a specific region found in the HCV proteins NS4B and NS5A, viral proteins that are absolutely required for virus replication. Disrupting the normal function of these two proteins provides for a new method of HCV treatment and should combat the emergence of drug resistance to new HCV polymerase and protease inhibitors that will be on the market in the near future.
